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Abstract
Purpose/Background
We aimed to describe changes in survival in alcoholic hepatitis (AH) over time by examining
published data.
Methods
A systematic literature search of Ovid Embase and PubMed was undertaken using the
MESH terms ‘hepatitis, alcoholic’ to identify randomised controlled trials (RCT) and observa-
tional studies (OS) in alcoholic hepatitis. Data were extracted from included studies regard-
ing 28-day, 90-day, 180-day mortality, as well as biochemical and clinical data.
Results
After review of the literature search results, 77 studies published between 1971 and 2016
were analysed, which included data from a total of 8,184 patients. Overall mortality from AH
was 26% at 28 days, 29% at 90 days and 44% at 180 days after admission. No changes in
mortality over time were observed in univariable analysis at 28 days or 90 days after admis-
sion (Pearson correlation r -0.216, p = 0.098, and r 0.121 p = 0.503 respectively). A small
but statistically significant increase in mortality was seen in 180-day mortality (r 0.461 p =
0.036). However, after meta-regression to adjust for other factors associated with mortality
at each time point, no changes in mortality were seen. Sub-group analysis did not reveal
any changes in mortality over time in different study types, or when only biopsy-proven or
severe disease were considered.
Conclusion
There has been no improvement in mortality from AH. This is not explained by changes in
severity of disease. This emphasises the urgent need for effective treatments for this alco-
holic hepatitis.
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Systematic review: Trends in survival from alcoholic hepatitis
Alcohol related liver disease (ArLD) is a common liver disease [1] and the leading cause of
liver-related deaths in the UK [2]. ArLD is a spectrum of disease ranging from simple steatosis
to cirrhosis [3]. Alcoholic hepatitis (AH) is the most florid manifestation of ArLD, typified by
acute jaundice and coagulopathy [4]. In spite of years of research AH is difficult to treat. Many
agents have been examined over the years without conspicuous success in the treatment of AH
[5–12]. Most recently the largest randomised controlled trial (RCT) in the field of ArLD failed
to show a clear benefit of corticosteroid therapy [13]. A small positive benefit on early mortal-
ity was found in network meta-analysis of several trials [14], however this was not supported
by the most recent direct meta-analysis [15], and any short-term benefits of corticosteroid are
not maintained in the longer-term.
In other areas of hepatology for example in acute liver failure [16], hepatocellular carcinoma
and viral hepatitis [17], medical not maintained in longer-term de recent reviews of therapy
for alcoholic hepatitis, published in 2015 and 2017 respectadvances have caused survival to
improve markedly over time. Similarly, decreases in mortality have been observed in common
non-hepatic disease such as acute myocardial infarction [18,19] and stroke [20,21]. We used
systematic review to examine the mortality of AH in trials and observational studies of AH to
evaluate changes over time.
Methods
A systematic review of studies in alcoholic hepatitis was undertaken, by searching PubMed
(1946–2016) EMBASE (1947 to 2016) using the search terms: (((alcoholic hepatitis) NOT non-
alcoholic) NOT B0 NOT C, limited to human studies and English language. Furthermore,
‘grey literature’ was examined by looking at reference lists of included studies for relevant
manuscripts (snowballing), and articles citing included studies were also reviewed (reverse
snowballing). Studies were included if they reported on patients with a clinical or histological
diagnosis of alcoholic hepatitis and provided information on mortality at 28 days, 90 days or
six months after admission. Only full papers published in English were considered for inclu-
sion. This protocol was not registered.
Data regarding mortality, biochemical severity (bilirubin, prothrombin time or INR, creati-
nine, white cell count) and participant characteristics (gender and age) were sought. These
data were extracted from included papers and entered into a pre-prepared spreadsheet. Two
authors (EH and LH) collected data independently and then combined data were checked by
all authors to identify inconsistencies. These were resolved by consensus. Missing data were
not imputed. The primary outcome considered was mortality from AH. Mortality over time
was calculated by considering the year of publication of included studies as a single time point,
rather than duration of a study. Overall mortality was noted, and in controlled trials, the mor-
tality in intervention and control groups in each study was also considered. We noted age,
alcohol intake, gender and laboratory measurements (bilirubin, creatinine, urea, prothrombin
time and white cell count). Where values were reported only for individual groups, overall
mean was calculated by the following formula: overall mean = [(ngroup 1/ntotal).(meangroup 1)]
+[(ngroup 2/ntotal).(meangroup 2)]. When the same cohort or overlapping data collection periods
were reported in separate papers, the cohort was included only once and the larger report
included. The risk of bias in included studies was assessed using the Cochrane risk of bias tool
for randomised studies [22] or the NIH tool for assessing bias in observational studies [23] as
appropriate.
Mortality at each time point was calculated as percentages. Correlation of mortality and
time was examined in univariable analysis using r2 values. Meta-regression analysis using
Survival in alcoholic hepatitis
PLOS ONE | https://doi.org/10.1371/journal.pone.0192393 February 14, 2018 2 / 10
linear regression was used to take into account other factors associated with mortality. Sensi-
tivity analyses of groups of differing types of study (randomised trials vs. observational stud-
ies), biopsy-controlled studies and studies incudling patients with severe disease (defined by
the discriminant function, DF) were undertaken in the same way. Statistical analysis was per-
formed with Stata version 23 (IBM, New York, USA).
Results
The literature search identified 3,691 papers. After exclusion of duplicate search results and
irrelevant or ineligible results a final group of 77 papers was included of which 44 were trials of
experimental treatments and 33 were observational studies (Fig 1). Of the observational
Fig 1. Study flowchart demonstrating literature search process.
https://doi.org/10.1371/journal.pone.0192393.g001
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studies, 29 were cohort studies and 4 were case-control studies. These studies described a total
of 8,184 participants– 4,100 in RCT and 4,084 in observational studies. The characteristics of
each study are summarised in S1–S5 Tables with references to individual studies. The risk of
bias was assessed in each study using established methods (S6 and S7 Tables).
Missing data was considerable, particularly regarding mortality beyond 28 days. The overall
number of participants contributing to each outcome of interest in summarised in S8 Table.
Diagnosis of alcoholic hepatitis was usually based on clinical grounds, particularly in observa-
tional studies. Biopsy was more common in trials including patients with AH but not univer-
sal. In total 2215 cases were biopsy-proven, representing 33% of all participants.
Mortality over time
When all studies where taken into consideration, average mortality from AH was 25% at 28
days after admission and 29% at 90 days after admission. This has not changed over time: uni-
variable analysis of trends over time showed no significant changeover time in 28-day mortal-
ity (Pearson correlation -0.216, p = 0.098, data from 61 studies, 6652 participants) (Fig 2), or
90-day mortality (correlation 0.121 p = 0.503, 52 studies, 5672 participants) (Fig 3). Overall
mortality at 180 days after admission was 38%. A small but statistically significant increase in
180-day mortality after admission was observed over time (correlation 0.461 p = 0.036, 21
studies, 2593 participants) (Fig 4). These findings are summarised in Table 1.
Meta-regression analysis
Creatinine, bilirubin, white cell count and age were associated with mortality (Table 2). More-
over these factors showed evidence of change over time. To analyse changes in mortality over
time whilst controlling for these factors, linear meta-regression was performed. In this analysis,
mortality did not significantly change over time at 28-days (beta -0.715, p = 0.058,), 90-days
(beta 0.571, p = 0.341) or 180-days (beta 0.552, p = 0.381) after admission with AH (Table 3).
Fig 2. 28-day mortality in alcoholic hepatitis over time. A individual studies B pooled data for each decade (mean +
SEM).
https://doi.org/10.1371/journal.pone.0192393.g002
Survival in alcoholic hepatitis
PLOS ONE | https://doi.org/10.1371/journal.pone.0192393 February 14, 2018 4 / 10
Subgroup analyses
Included studies were grouped according to the type of study: therapeutic trials or observa-
tional studies. The frequency of biopsy proven diagnosis of AH, and severity of disease was
also considered.
When considering therapeutic trials only, no statistically significant change in mortality
over time was observed at each time point: 28-day mortality, Pearson correlation -0.305
p = 0.055, (40 studies, 3888 participants), 90-day mortality, correlation 0.152 p = 0.619
Fig 3. 90-day mortality in alcoholic hepatitis over time. A individual studies B pooled data for each decade (mean +
SEM).
https://doi.org/10.1371/journal.pone.0192393.g003
Fig 4. 180-day mortality in alcoholic hepatitis over time. A individual studies B pooled data for each decade (mean +
SEM).
https://doi.org/10.1371/journal.pone.0192393.g004
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(13 studies, 2054 participants), 180-day mortality (correlation 0.455 p = 0.187, 10 studies, 1041
participants). When intervention and control groups were considered separately, a small but
statistically significant improvement in 28-day mortality was seen in control groups (Pearson
correlation -0.341, p-0.034)(Table 1). After controlling for other factors associated with mor-
tality in meta-regression, this association was no longer significant (beta -0.538, p = 0.231).
In observational studies, no changes in mortality were seen at 28-days (correlation 0.276
p = 0.214, 22 studies, 2958 participants), 90-days (correlation 0.200, p = 0.475, 20 studies,
2604 participants) or 180-days, (correlation -0.354, p = 0.491, 11 studies, 3581 participants)
(Table 1).
When considering studies that only included biopsy-proven AH (16 studies, 2215 partici-
pants), no change in mortality over time was seen at any time point: 28-days (correlation
Table 1. Pearson correlation between year of study and time-point mortality in acute alcoholic hepatitis.
28-day mortality p 90-day mortality p 180-day mortality p
Overall -0.216 0.098 0.121 0.503 0.461 0.036
Sub-group analyses
RCT -0.305 0.055 0.152 0.619 0.455 0.187
RCT Intervention groups -0.259 0.117 -0.80 0.814 0.502 0.169
RCT Control groups -0.341 0.033 -0.077 0.821 0.474 0.197
OS 0.276 0.214 0.200 0.475 -0.354 0.491
Biopsy proven 0.078 0.801 0.009 0.979 -0.499 0.208
Severe disease (mDF >32) -0.130 0.419 0.342 0.95 0.110 0.707
significant at p<0.05
https://doi.org/10.1371/journal.pone.0192393.t001
Table 2. Factors associated with mortality in alcoholic hepatitis and their change over time.
Mortality
28-day mortality 90-day mortality 180-day mortality Change over time
Prothrombin time
seconds
Correlation -0.093 -0.019 0.059 0.295
p 0.565 0.938 0.856 0.037
Creatinine
mg/dL
Correlation 0.359 0.184 0.314 -0.358
p 0.034 0.464 0.321 0.015
Bilirubin
mg/dL
Correlation 0.496 0.655 0.597 -0.134
p <0.001 0.001 0.031 0.307
White cell count
x109/L
Correlation 0.561 0.515 0.548 -0.497
p 0.001 0.034 0.127 0.001
Age
years
Correlation -0.522 -0.390 0.132 0.214
p 0.007 0.135 0.700 0.223
Gender
% male
Correlation -0.077 -0.004 -0.255 -0.156
p 0.776 0.989 0.626 0.477
https://doi.org/10.1371/journal.pone.0192393.t002
Table 3. Meta-regression of mortality over time. Data are beta values from linear regression to control for other factors associated with mortality.
28-day mortality p 90-day mortality p 180-day mortality p
Overall 0.715 0.058 0.571 0.341 0.552 0.381
Sub-group analyses
RCT control group -0.538 0.231
https://doi.org/10.1371/journal.pone.0192393.t003
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0.078 p = 0.801, 13 studies, 1459 participants), 90-days (correlation -0.009, p = 0.979, 10 stud-
ies, 970 participants) or 180-days, (correlation -0.499, p = 0.208, 8 studies, 1179 participants)
(Table 1).
Finally, to eliminate non-severe alcoholic hepatitis we performed sub-group analysis
including only those studies that had a mean discriminant function (DF) above 32. This
excluded 13 studies that did not report an average DF, or data to allow the DF to be calculated,
and 11 studies with a mean DF below 32. This left a group of 54 studies including 6503 partici-
pants. Once again, we saw no changes in mortality over time: in 28-day mortality (correlation
-0.130 p = 0.419, 41 studies, 5268 participants), 90-days (correlation 0.342, p = 0.95, 25 studies,
4645 participants) or 180-days, (correlation -0.110, p = 0.707, 14 studies, 2473 participants)
(Table 1).
Discussion
Alcoholic hepatitis is an acute, life-threatening type of alcoholic liver disease. There has been
ongoing research for many years in AH and many therapeutic agents have been examined for
efficacy. However, our data show that mortality from AH has not improved over more than
four decades. Indeed we found a small but significant increase in mortality at 180-days. This
observation remained when considering only therapeutic trials where inclusion and exclusion
criteria may have been more stringent. These results demonstrate the urgent need for better
treatment in AH.
The strength of this analysis rests on the use of robust systematic review to obtain a com-
prehensive data set of studies in AH over the past few decades. Despite some missing data,
particularly for outcomes beyond 28 days, this dataset was large enough to allow associations
to be tested in univariable and multivariable analysis. In terms of limitations of the data, our
conclusions depend on aggregate data reported in studies, where individual patient data may
give more reliable results. However the difficulties in obtaining such data is considerable
especially with older studies. The apparent increase in 6-month mortality is likely due to the
small number of trials reporting this longer outcome in the 1970s. Information on cause of
death would be valuable as this may have changed over time, however this was rarely
reported.
Our data are consistent with previous work examining outcomes over time in liver disease.
Analysis of survival of people with liver disease after discharge from hospitals in England from
1968–1999 found no improvement in 1-month or 1-year survival over time [24]. It is notable
that the majority of this cohort had alcohol related liver disease, although interestingly the
overall survival was much better for patients with AH compared to decompensated cirrhosis.
Although there may be some methodological concerns over these data [25], given that there
are no new specific treatments for ArLD that have emerged since these data were reported (in
contrast to other causes of chronic liver disease) it is reasonable to think that the data remain
relevant.
Whilst progress towards novel specific treatments in AH has been frustratingly slow, it
might be expected that improvements in medical care of acutely unwell patients would have a
positive effect on outcomes. Our results do not support this. In other areas of hepatology for
example variceal bleeding or decompensated cirrhosis clear and standardised care bundles are
used [26] that revolve around early assessment and administration of prophylactic antibiotics
for example. Many patients with AH present to non-specialist medical services, where a stan-
dardised care bundle may allow for better treatment in the early stages of disease. Equally
important is the ongoing pursuit of better treatments for AH that may make a significant
impact on outcomes. This is especially pertinent given the underwhelming evidence for the
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efficacy of corticosteroids [15] which had been by many seen as central to the treatment of AH
[27], despite conflicting trial data.
In conclusion, review of the available literature regarding mortality in alcoholic hepatitis
over four decades shows no evidence of improvement in short-term mortality over time. This
is in contrast to significant improvements in outcome in other liver diseases and other preva-
lent medical conditions.
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